A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Neihulizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 28 Mar 2017 Status changed from suspended to discontinued.
- 05 Dec 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.
- 05 Dec 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.